How GLP-1 Receptor Agonists Are Transforming Obesity Treatment and Elevating Novo Nordisk and Eli Lilly beyond Mega Cap status.

Apr 13, 2024

∙ Paid

The evolution of GLP-1 receptor agonists has been nothing short of remarkable. Initially developed for type 2 diabetes, it is now revolutionizing obesity treatment and catapulting Novo Nordisk and Eli Lilly into the champions league of companies.

Let’s have a quick look at the financials. First up is Novo Nordisk:

Keep reading with a 7-day free trial

Subscribe to Kontra Investments to keep reading this post and get 7 days of free access to the full post archives.